Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis

Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis

Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis r...

Full description

Bibliographic Details
Main Authors: Mary Catherine G. Pangilinan, Peerada Sermswan, Pravit Asawanonda
Format: Article
Language:English
Published: Karger Publishers 2020-08-01
Series:Case Reports in Dermatology
Subjects:
biologic treatment
ixekizumab
secukinumab
hiv psoriasis
anti-il-17
erythrodermic psoriasis
Online Access:https://www.karger.com/Article/FullText/508781
Description
Summary:Psoriasis is an immune-mediated skin disease with various presentations. HIV infection affects the immune system and aggravates psoriasis lesions. Therefore, psoriasis management in HIV patients poses a great challenge for dermatologists. In this report, 2 HIV patients with erythrodermic psoriasis received anti-IL-17 and experienced significant clearance of lesions. No recurrence or opportunistic infection was noted. In conclusion, anti-IL-17 monoclonal antibodies are an effective and promising treatment option for HIV-infected patients with psoriasis.
ISSN:1662-6567

Similar Items